WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010028055) INSULIN WITH A BASAL RELEASE PROFILE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/028055    International Application No.:    PCT/US2009/055746
Publication Date: 11.03.2010 International Filing Date: 02.09.2009
Chapter 2 Demand Filed:    01.07.2010    
IPC:
A61K 9/00 (2006.01), A61K 45/06 (2006.01), A61K 38/28 (2006.01)
Applicants: BIODEL, INC. [US/US]; 100 Saw Mill Road Danbury, CT 06810 (US) (For All Designated States Except US).
POHL, Roderike [US/US]; (US) (For All Designated States Except US).
KASHYAP, Nandini [IN/US]; (US) (For US Only).
HAUSER, Robert [US/US]; (US) (For US Only).
OZHAN, Koray [TR/US]; (US) (For US Only).
STEINER, Solomon, S. [US/US]; (US) (For US Only)
Inventors: POHL, Roderike; (US).
KASHYAP, Nandini; (US).
HAUSER, Robert; (US).
OZHAN, Koray; (US).
STEINER, Solomon, S.; (US)
Agent: PABST, Patrea, L.; Pabst Patent Group LLP 1545 Peachtree Street, N.E. Suite 320 Atlanta, GA 30309 (US)
Priority Data:
61/238,024 28.08.2009 US
61/093,604 02.09.2008 US
61/142,596 05.01.2009 US
Title (EN) INSULIN WITH A BASAL RELEASE PROFILE
(FR) INSULINE DOTÉE D’UN PROFIL DE LIBÉRATION BASAL
Abstract: front page image
(EN)A clear basal insulin formulation composed of insulin (preferably human recombinant insulin), buffering agents, precipitating agents, and/or stabilizing agents for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing "basal insulin" over a period of 12 to 24 hours, which can be varied by compositional changes to tailor the release profile to the needs of the individual diabetic patient.
(FR)La présente invention porte sur une formulation d'insuline basale limpide composée d'insuline (de préférence, d'insuline recombinante humaine), de tampons, d'agents de précipitation et/ou d'agents de stabilisation destinée à une administration sous-cutanée, intradermique ou intramusculaire. La formulation est conçue pour constituer un précipité d'insuline à la suite de l'injection, créant une libération lente d’« insuline basale » sur une période de 12 à 24 heures, qui peut être amenée à varier par des modifications de composition afin de personnaliser le profil de libération correspondant aux besoins du patient diabétique individuel.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)